Biocon's total inventories for the quarter that ended in Mar. 2026 was ₹60,857 Mil. Biocon's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was ₹30,429 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Biocon's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ₹-110.45.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Biocon's Days Inventory for the
three
months ended in Mar. 2026 was 198.43.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Biocon's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.46.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biocon's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.68.
Biocon (NSE:BIOCON) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Biocon's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biocon's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Biocon Total Inventories Related Terms
Biocon Total Inventories Historical Data
* Premium members only.
The historical data trend for Biocon's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of ₹60,857 Mil mean?
Biocon (NSE:BIOCON) has a Total Inventories of ₹60,857 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Biocon and its competitors.
Is Biocon's Total Inventories too high?
Biocon's current Total Inventories is ₹60,857 Mil. Overall, Biocon has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocon's Total Inventories compare to VRTX and REGN?
Biocon's Total Inventories of ₹60,857 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Biocon and its competitors. Biocon's current Total Inventories is ₹60,857 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocon stock overvalued right now?
Based on GuruFocus' analysis, Biocon (NSE:BIOCON) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹339.70, compared to a current price of ₹426.80 — trading 25.6% above its estimated fair value. The current Total Inventories is ₹60,857 Mil. Biocon's overall GF Score™ is 89/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Biocon (NSE:BIOCON), the current Total Inventories is ₹60,857 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocon (NSE:BIOCON) Overvalued in 2026?
Based on GuruFocus' analysis, Biocon stock appears to be overvalued.
The current stock price of ₹426.80 is trading 25.6% above its estimated GF Value™ of ₹339.70.
GuruFocus considers Biocon to be Modestly Overvalued.
Key valuation signals for NSE:BIOCON:
Total Inventories: ₹60,857 Mil
GF Value™: ₹339.70 vs. price of ₹426.80 (25.6% above fair value)
No single metric tells the full story. See the NSE:BIOCON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
89GF Score
Get the complete analysis for NSE:BIOCON
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BIOCON has been successfully added to your 
